CVRx Expands Barostim Trial to Broader Heart Failure Population
Event summary
- CVRx initiates BENEFIT-HF trial, a landmark study evaluating Barostim in a significantly expanded heart failure population.
- Trial will randomize 2,500 patients across 150 centers in the U.S. and Germany, with enrollment beginning in the first half of 2026.
- BENEFIT-HF targets patients with LVEF <50% and NT-proBNP levels <5,000 pg/mL, tripling the potential indicated patient population.
- CMS approved Category B IDE coverage for the trial, supporting patient access and reinforcing feasibility at scale.
The big picture
CVRx's BENEFIT-HF trial represents a strategic pivot to address a broader heart failure population, building on the success of its BeAT-HF trial. The expansion of patient criteria could significantly increase the addressable market for Barostim, positioning CVRx as a leader in neuromodulation-based heart failure therapies. The trial's scale and CMS support underscore the company's commitment to advancing heart failure care.
What we're watching
- Trial Execution
- The pace at which CVRx can enroll 2,500 patients across 150 centers will determine the trial's timeline and potential outcomes.
- Regulatory Impact
- Whether CMS's Category B IDE coverage will facilitate broader adoption of Barostim if the trial succeeds.
- Market Expansion
- How a successful trial could triple the indicated patient population and drive revenue growth for CVRx.